Clinical trial Recruiting at 1 site Interventional Ages 18 and up

AI-assisted written information for hemorrhoidal disease treatment

Official title: Effect of AI-Assisted Written Patient Information on Medical Treatment Adherence and Short-Term Patient-Reported Outcomes in Symptomatic Hemorrhoidal Disease: A Prospective Randomized Controlled Trial

Run by Sanliurfa Education and Research Hospital · NCT07701798 · Data updated 2026-11-12

In adults with symptomatic hemorrhoids, this trial tests whether AI-generated written information helps people stick to their conservative treatment plan better than standard verbal counseling.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment220 (estimated)
SponsorSanliurfa Education and Research Hospital
Government
Locations1 site (Sanliurfa, Şanlıurfa)
StatusRecruiting
StartedJuly 15, 2026
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedSeptember 2, 2026
Trial IDNCT07701798 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years or older with symptomatic hemorrhoidal disease planned for conservative/medical treatment and who can read Turkish.

Probably not a fit

Patients who may not benefit include those unable to adhere to follow-up or who require procedures beyond conservative management.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, randomized controlled trial comparing two approaches to patient information in adults with symptomatic hemorrhoidal disease planned to receive initial conservative therapy. Participants are randomly assigned to receive either standard verbal counseling or AI-assisted written information containing the same medical content. Both groups receive identical medical treatment, with assessments at baseline, day 7, day 14, and day 28 to evaluate treatment adherence, quality of life, symptom changes, and healthcare utilization.

Why it matters

Potential benefit: If successful, AI-assisted written information could improve adherence and symptoms, potentially leading to better outcomes.

How similar studies have gone: Prior studies in other conditions have shown that providing AI-assisted or enhanced written information can improve patient engagement and adherence, but evidence in hemorrhoidal disease is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age 18 years or older
2. Diagnosis of symptomatic hemorrhoidal disease in the outpatient clinic
3. Conservative/medical treatment planned at first evaluation
4. Ability to read and understand Turkish
5. Reachable by telephone
6. Provision of written informed consent

Exclusion Criteria:

1. Planned office procedure or surgery
2. Emergency conditions such as thrombosed external hemorrhoid, strangulation, or massive bleeding
3. Concomitant anal fissure, anal fistula, perianal abscess, inflammatory bowel disease, or suspicion of anal/colorectal malignancy
4. History of hemorrhoidal intervention or surgery within the last 3 months
5. Severe cognitive impairment, severe visual problem, or communication barrier
6. Pregnancy and postpartum period
7. Serious systemic conditions that would prevent completion of study follow-up

Where it's running

  • Sanliurfa Education and Research Hospital
    Sanliurfa, Şanlıurfa, Turkey (Türkiye)
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.